Abstract
Technetium-99m (V)-dimercaptosuccinic acid (DMSA) is a tumour-imaging agent which has been used to evaluate medullary thyroid cancer and soft tissue tumours. Physiological uptake has been demonstrated in the kidneys, nasal mucosa and blood pool. In addition to positive accumulation in these sites, uptake in the breasts has been noted. The purpose of this retrospective study was to evaluate the accumulation of99mTc (V)-DMSA in the normal breasts of 83 patients. There was no accumulation in male breasts. On the other hand, 24 of 51 female patients showed bilateral symmetrical accumulation in the breasts. Positive uptake was seen in 16 of 23 patients (70%) between 15 and 50 years old, but in only 7 of 25 (28%) above 50 years old. One out of three patients (33%) under 15 years old showed positive breast uptake. In conclusion, the female breasts should be included in the description of a pattern of normal biodistribution of99mTc (V)-DMSA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yokoyama A, Hata N, Horiuchi K, et al. The design of a pentavalent99mTc-dimercaptosuccinic complex as a tumour imaging agent.Int J Nucl Med 1985; 12: 273–279.
Kobayashi H, Sakahara H, Hosono M, et al. Soft-tissue tumor: diagnosis with Tc-99m(V) dimercaptosuccinic acid scintigraphy.Radiology 1994; 190: 277–280.
Ohta H, Endo K, Konishi J, et al. Scintigraphic evaluation of aggressive fibromatosis.J Nucl Med 1990; 31: 1632–1634.
Ohta H, Yamamoto K, Endo K, et al. A new imaging agent for medullary carcinoma of the thyroid.J Nucl Med 1984; 25: 323–325
Ohta H, Endo K, Fujita T, et al. Imaging of head and neck tumours with technetium (V)-99mTc DMSA: a new tumour seeking agent.Clin Nucl Med 1985; 10: 855–860.
Clarke SEM, Lazarus CR, Wraight P, et al. Pentavalent (99mTc)DMSA, (131I)MIBG, (99mTc)MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.J Nucl Med 1988; 29: 33–38.
Watkinson JC, Lazarus CR, Mistry R, Shaheen OH, Maisey MN, Clarke SE. Technetium-99m(V) dimercaptosuccinic acid uptake in patients with head and neck squamous carcinoma: experience in imaging.J Nucl Med 1989; 30: 174–180.
Kobayashi H, Horiuchi K, Sakahara H, et al. Oxygen bubbling can improve the labelling of pentavalent technetium-99m dimercaptosuccinic acid.Eur J Nucl Med 1995; 22: 559–562.
Watkinson JC, Lazarus CR, Maisey MN, et al. 99-Tcm(V) DMSA: the pituitary sign.Nucl Med Commun 1990; 11: 313–317.
Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid.Surgery 1993; 114: 1083–1089.
Kim YC, Brown ML, Thrall JH. Scintigraphic patterns of gallium-67 uptake in the breast.Radiology 1977; 124: 169–175.
Lam ASK, Puncher MRB, Blower PJ. In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid.Eur J Nucl Med 1996; 23: 1575–1582.
Mudun A, Unal S, Ilhan R, et al. False-positive uptake of Tc99m penta-DMSA in fibrous dysplasia of breast in a patient with medullary carcinoma of thyroid.Clin Nucl Med 1994; 19: 364–365.
Kashyap R, Babbar A, Sahai I, et al. Tc-99m(V) DMSA imaging: a new approach to studying metastasis form breast carcinoma.Clin Nucl Med 1992; 17: 119–122.
Ajmani SK, Pircher FJ. Ga-67 citrate in gynecomastia.J. Nucl Med 1978; 19: 560–561
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakamoto, Y., Sakahara, H., Kobayashi, H. et al. Technetium-99m (V)-dimercaptosuccinic acid: Normal accumulation in the breasts. Eur J Nucl Med 24, 1146–1148 (1997). https://doi.org/10.1007/BF01254247
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01254247